Patents by Inventor Chabrier De Lassauniere

Chabrier De Lassauniere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9918967
    Abstract: The invention relates to the use of derivatives of thiazoles having general formula (I) for the preparation of a medicament for the treatment or prevention of dyskinesias caused by a chemical treatment. The invention also relates to a combination of thiazole derivatives having general formula (I) and at least one compound selected from among neuroleptics or products that act on the dopaminergic system for the treatment or prevention of dyskinesias caused by a chemical treatment.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: March 20, 2018
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Pierre-Etienne Chabrier de Lassauniere, Michel Auguet, Brigitte Spinnewyn
  • Patent number: 9259458
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 16, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
  • Patent number: 9176119
    Abstract: The invention relates to a method for determining the kinetics of action of a cholinergic neurotoxin as well as a method for determining the quantity of neurotoxin in a sample.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: November 3, 2015
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: José-Antonio Camara-Ferrer, Michael Auguet, Pierre-Etienne Chabrier De Lassauniere
  • Publication number: 20150238468
    Abstract: The invention relates to the use of derivatives of thiazoles having general formula (I) for the preparation of a medicament for the treatment or prevention of dyskinesias caused by a chemical treatment. The invention also relates to a combination of thiazole derivatives having general formula (I) and at least one compound selected from among neuroleptics or products that act on the dopaminergic system for the treatment or prevention of dyskinesias caused by a chemical treatment.
    Type: Application
    Filed: March 6, 2015
    Publication date: August 27, 2015
    Inventors: Pierre-Etienne CHABRIER DE LASSAUNIERE, Michael AUGUET, Brigitte SPINNEWYN
  • Patent number: 9080220
    Abstract: The present invention relates to a composition comprising: at least one botulinum neurotoxin, and at least one opiate derivative or its salt. The invention also relates to a product comprising at least one botulinum neurotoxin and at least one opiate derivative or its salt, as a combination product for simultaneous, separate or sequential therapeutic use in the treatment or prevention of pain and of neuromuscular disorders.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: July 14, 2015
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Michel Auguet, Christine Favre, Pierre-Etienne Chabrier De Lassauniere
  • Patent number: 9006274
    Abstract: The invention relates to the use of derivatives of thiazoles having general formula (I) for the preparation of a medicament for the treatment or prevention of dyskinesias caused by a chemical treatment. The invention also relates to a combination of thiazole derivatives having general formula (I) and at least one compound selected from among neuroleptics or products that act on the dopaminergic system for the treatment or prevention of dyskinesias caused by a chemical treatment.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: April 14, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Pierre-Etienne Chabrier De Lassauniere, Michel Auguet, Brigitte Spinnewyn
  • Patent number: 8921322
    Abstract: The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: December 30, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere
  • Patent number: 8784841
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: July 22, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
  • Publication number: 20140154781
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Christine FAVRE, Michel AUGUET, Piere-Etienne CHABRIER DE LASSAUNIERE
  • Patent number: 8642591
    Abstract: The present invention relates to a composition containing at least one amidine derivative or carboxamide derivative of general formula (I) or (A) in combination with at least one compound chosen from steroids, corticoids or corticosteroids, wherein said composition is suitable for the preparation of a medicament.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: February 4, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Bernadette Pignol, Serge Auvin, Dennis Bigg, Pierre-Etienne Chabrier de Lassauniere
  • Patent number: 8288560
    Abstract: The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R1 and R2 are notably independently hydrogen, alkyl or cycloalkyl and ? is —NR46R47 or —OR48, R46 and R47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH2)k—COOR51, R51 is notably alkyl or haloalkyl and R48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: October 16, 2012
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Pierre-Etienne Chabrier De Lassauniere, Jeremiah Harnett, Dennis Bigg, Anne-Marie Liberatore, Jacques Pommier, Jacques Lannoy, Christophe Thurieau
  • Patent number: 8273359
    Abstract: The present invention relates to a method of treating or preventing pain or pains induced by an anti-neoplastic agent, comprising the step of administering an effective amount of at least one botulinum neurotoxin to a patient in need thereof.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: September 25, 2012
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere
  • Publication number: 20110172434
    Abstract: The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R1 and R2 are notably independently hydrogen, alkyl or cycloalkyl and ? is —NR46R47 or —OR48, R46 and R47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH2)k—COOR51, R51 is notably alkyl or haloalkyl and R48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 14, 2011
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Pierre-Etienne CHABRIER DE LASSAUNIERE, Jeremiah Harnett, Dennis Bigg, Anne-Marie Liberatore, Jacques Pommier, Jacques Lannoy, Christophe Thurieau
  • Patent number: 7956075
    Abstract: The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R1 and R2 are notably independently hydrogen, alkyl or cycloalkyl and ? is —NR46R47 or —OR48, R46 and R47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH2)k—COOR51, R51 is notably alkyl or haloalkyl and R48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: June 7, 2011
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Pierre-Etienne Chabrier De Lassauniere, Jeremiah Harnett, Dennis Bigg, Anne-Marie Liberatore, Jacques Pommier, Jacques Lannoy, Christophe Thurieau
  • Publication number: 20110038893
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Application
    Filed: April 27, 2009
    Publication date: February 17, 2011
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
  • Patent number: 7838009
    Abstract: The invention relates to the use of a pre-synaptic neuromuscular blocking substance for preparing a medicament intended to treat a gland, organ or duct obstructed by a naturally formed stone. This method can be applied notably for salivary gland, gall bladder, kidney or pancreas stones.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: November 23, 2010
    Assignees: Ipsen Pharma S.A.S., Ipsen Biopharm Limited
    Inventors: Pierre Bernard D'Arbigny, Piere-Etienne Chabrier De Lassauniere, Alan Barcock
  • Patent number: 7696197
    Abstract: The invention concerns the use of a phenothiazine derivative of formula (I), wherein: R represents the hydrogen atom, an alkyl radical, arylalkyl, or —C(O)R?, for preparing a medicine for preventing and/or treating hearing loss.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: April 13, 2010
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques
    Inventors: Bernadette Pignol, Jean-Luc Puel, Serge Auvin, Pierre-Entienne Chabrier de Lassauniere, Jing Wang
  • Publication number: 20100068231
    Abstract: The present invention relates to a method of treating or preventing pain or pains induced by an anti-neoplastic agent, comprising the step of administering an effective amount of at least one botulinum neurotoxin to a patient in need thereof.
    Type: Application
    Filed: October 26, 2007
    Publication date: March 18, 2010
    Inventors: Christine Favre, Michel Auguet, Pierrre-Etienne Chabrier De Lassauniere
  • Patent number: 7659266
    Abstract: The invention concerns amidine derivatives of general formula (I) exhibiting an inhibitory activity of calpains and/or a trapping activity of reactive forms of oxygen.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: February 9, 2010
    Assignee: S.C.R.A.S.
    Inventors: Serge Auvin, Dennis Bigg, Pierre-Etienne Chabrier De Lassauniere, Bernadette Pignol
  • Publication number: 20100029566
    Abstract: The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus.
    Type: Application
    Filed: December 17, 2007
    Publication date: February 4, 2010
    Applicant: IPSEN PHARMA S.A.S
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere